• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 421010 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414268786 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414268786 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Acadia Pharmaceuticals Shares Climbing Higher, Up 2.6%

Published on Mon, 01/14/2013 - 11:15
By Adrienne Chilton

Acadia Pharmaceuticals (NASDAQ:ACAD) is a company whose shares are active, trading 2.6% higher to $5.14. The S&P is trading lower by 0.2% to 1,469 and the Dow is trading fractionally lower to 13,484.

There is potential upside of 62.6% for shares of Acadia Pharmaceuticals based on a current price of $5.14 and an average consensus analyst price target of $8.36. The stock should find initial support at its 50-day moving average (MA) of $3.87 and further support at its 200-day MA of $2.32.

Over the past year, Acadia Pharmaceuticals has traded in a range of $1.24 to $6.54 and is now at $5.14, 315% above that low. Over the past week, the 200-day moving average (MA) has gone up 3.1% while the 50-day MA has advanced 7.4%.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

By Adrienne Chilton
achilton@fnno.com

Latest News from FNNO

Shares of Travelers Rise Above Previous ...

Shares of Travelers (NYSE:TRV) traded today at $97.70, breaking its 52-week high. Appr ...

Shares of Transglobe Energy Fall to a Ne...

Transglobe Energy (NASDAQ:TGA) traded today at a new 52-week low of $4.66. So far toda ...

Shares of Teleflex Have Risen Above Prev...

Shares of Teleflex (NYSE:TFX) traded today at $111.56, breaking its 52-week high. Appr ...

Southwest Gas: 52-Week High Recently Ecl...

Southwest Gas (NYSE:SWX) traded today at a new 52-week high of $56.15. So far today ap ...

Shares of Southwestern Energy Have Falle...

Shares of Southwestern Energy (NYSE:SWN) traded at a new 52-week low today of $31.28. ...

Shares of Sovran Self Storage Rise to a ...

Shares of Sovran Self Storage (NYSE:SSS) traded today at $82.98, breaking its 52-week h ...

Recent 52-Week High Exceeded in Shares o...

Sonic (NASDAQ:SONC) traded at a new 52-week high today of $24.92. So far today approxi ...

Super Micro Computer: The Winning Streak...

Super Micro Computer (NASDAQ:SMCI) traded today at a new 52-week high of $31.00. This ...